Advances in Frontline Management of Peripheral T-cell Lymphoma
- Author(s)
- Abeyakoon, C; van der Weyden, C; Harrop, S; Khot, A; Dickinson, M; Yannakou, CK; Prince, HM;
- Details
- Publication Year 2021-06,Volume 21,Issue #6,Page 368-378
- Journal Title
- Clinical Lymphoma, Myeloma & Leukemia
- Publication Type
- Review
- Abstract
- Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of lymphomas that are frequently associated with a poor prognosis. For many decades, the standard-of-care has been CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone)-based therapy, but it is well-recognized that survival outcomes are unsatisfactory, especially when compared with B-cell lymphomas. Major recent advances in cancer diagnosis and management have the potential to significantly improve PTCL outcomes. These include: (1) improved diagnostic techniques that incorporate molecular genetic data to further refine diagnosis and subtyping; (2) the development of novel agents; and (3) improved monitoring modalities, such as (18)F-fluorodeoxyglucose positron emission tomography-computed tomography scans and circulating tumor DNA. In this review, we aim to explore these 3 advances in the context of frontline management of PTCL.
- Keywords
- Biomarkers, Tumor; Clinical Decision-Making; Clinical Trials as Topic; Combined Modality Therapy/adverse effects/methods; Diagnosis, Differential; Diagnostic Imaging/methods; Disease Management; Humans; Lymphoma, T-Cell, Peripheral/diagnosis/etiology/mortality/*therapy; Molecular Diagnostic Techniques; Monitoring, Physiologic; Population Surveillance; Prognosis; Treatment Outcome; Disease monitoring; Hematopoietic stem cell transplantation; Molecular diagnostics; Novel agents; Radiotherapy
- Department(s)
- Haematology
- PubMed ID
- 33610499
- Publisher's Version
- https://doi.org/10.1016/j.clml.2021.01.012
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2025-05-16 07:57:39
Last Modified: 2025-05-16 07:58:33